Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 10/2009

01-10-2009 | Article

Height growth velocity, islet autoimmunity and type 1 diabetes development: the Diabetes Autoimmunity Study in the Young

Authors: M. M. Lamb, X. Yin, G. O. Zerbe, G. J. Klingensmith, D. Dabelea, T. E. Fingerlin, M. Rewers, J. M. Norris

Published in: Diabetologia | Issue 10/2009

Login to get access

Abstract

Aims/hypothesis

Larger childhood body size and rapid growth have been associated with increased type 1 diabetes risk. We analysed height, weight, BMI and velocities of growth in height, weight and BMI, for association with development of islet autoimmunity (IA) and type 1 diabetes.

Methods

Since 1993, the Diabetes Autoimmunity Study in the Young (DAISY) has followed children at increased type 1 diabetes risk, based on HLA-DR, -DQ genotype or family history, for the development of IA and type 1 diabetes. IA was defined as the presence of autoantibodies to insulin, GAD or protein tyrosine phosphatase islet antigen 2 twice in succession, or autoantibody-positive on one visit and diabetic at the next consecutive visit within 1 year. Type 1 diabetes was diagnosed by a physician. Height and weight were collected starting at age 2 years. Of 1,714 DAISY children <11.5 years of age, 143 developed IA and 21 progressed to type 1 diabetes. We conducted Cox proportional hazards analysis to explore growth velocities and size measures for association with IA and type 1 diabetes development.

Results

Greater height growth velocity was associated with IA development (HR 1.63, 95% CI 1.31–2.05) and type 1 diabetes development (HR 3.34, 95% CI 1.73–6.42) for a 1 SD difference in velocity.

Conclusions/interpretation

Our study suggests that greater height growth velocity may be involved in the progression from genetic susceptibility to autoimmunity and then to type 1 diabetes in pre-pubertal children.
Appendix
Available only for authorised users
Literature
1.
Johnston C, Millward BA, Hoskins P, Leslie RD, Bottazzo GF, Pyke DA (1989) Islet-cell antibodies as predictors of the later development of type 1 (insulin-dependent) diabetes. A study in identical twins. Diabetologia 32:382–386PubMedCrossRef
2.
Bonifacio E, Bingley PJ, Shattock M et al (1990) Quantification of islet-cell antibodies and prediction of insulin-dependent diabetes. Lancet 335:147–149PubMedCrossRef
3.
Onkamo P, Vaananen S, Karvonen M, Tuomilehto J (1999) Worldwide increase in incidence of Type I diabetes—the analysis of the data on published incidence trends. Diabetologia 42:1395–1403PubMedCrossRef
4.
EURODIAB ACE Study Group (2000) Variation and trends in incidence of childhood diabetes in Europe. EURODIAB ACE Study Group. Lancet 355:873–876CrossRef
5.
Pundziute-Lycka A, Dahlquist G, Nystrom L et al (2000) The incidence of Type 1 diabetes has not increased but shifted to a younger age at diagnosis in the 0–34 years group in Sweden 1983 to 1998. Diabetologia 45:783–791
6.
Weets I, de Leeuw IH, Du Caju MVL et al (2002) The incidence of type 1 diabetes in the age group 0–39 years has not increased in Antwerp (Belgium) between 1989 and 2000: evidence for earlier disease manifestation. Diabetes Care 25:840–846PubMedCrossRef
7.
Dahlquist G (2006) Can we slow the rising incidence of childhood-onset autoimmune diabetes? The overload hypothesis. Diabetologia 49:20–24PubMedCrossRef
8.
Wilkin TJ (2001) The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes. Diabetologia 44:914–922PubMedCrossRef
9.
Knip M, Reunanen A, Virtanen SM, Nuutinen M, Viikari J, Akerblom HK (2008) Does the secular increase in body mass in children contribute to the increasing incidence of type 1 diabetes? Pediatr Diabetes 9:46–49PubMedCrossRef
10.
Waldhor T, Schober E, Rami B (2003) Regional distribution of risk for childhood diabetes in Austria and possible association with body mass index. Eur J Pediatr 162:380–384PubMed
11.
Dabelea D, D’Agostino RB, Mayer-Davis EJ et al (2006) Testing the accelerator hypothesis: body size, beta-cell function, and age at onset of type 1 (autoimmune) diabetes. Diabetes Care 29:290–294PubMedCrossRef
12.
Betts P, Mulligan J, Ward P, Smith B, Wilkin TJ (2004) Increasing body weight predicts the earlier onset of insulin-dependent diabetes in childhood: testing the ‘accelerator hypothesis’ (2). Diabet Med 22:144–151CrossRef
13.
Kibirige M, Metcalf B, Renuka R, Wilkin TJ (2003) Testing the accelerator hypothesis: the relationship between body mass and age at diagnosis of type 1 diabetes. Diabetes Care 26:2865–2870PubMedCrossRef
14.
Knerr I, Wolf J, Reinehr T et al (2005) The ‘accelerator hypothesis’: relationship between weight, height, body mass index and age at diagnosis in a large cohort of 9,248 German and Austrian children with type 1 diabetes mellitus. Diabetologia 48:2501–2504PubMedCrossRef
15.
O’Connell MA, Donath S, Cameron FJ (2007) Major increase in type 1 diabetes: no support for the Accelerator Hypothesis. Diabet Med 24:920–923PubMedCrossRef
16.
17.
Giménez M, Aguilera E, Castell C, de Lara N, Nicolau J, Conget I (2007) Relationship between BMI and age at diagnosis of type 1 diabetes in a Mediterranean area in the period of 1990–2004. Diabetes Care 30:1593–1595PubMedCrossRef
18.
Bruining GJ (2000) Association between infant growth before onset of juvenile type-1 diabetes and autoantibodies to IA-2. Netherlands Kolibrie Study Group of Childhood Diabetes. Lancet 356:655–656PubMedCrossRef
19.
DiLiberti JH, Carver K, Parton E, Totka J, Mick G, McCormick K (2002) Stature at time of diagnosis of type 1 diabetes mellitus. Pediatrics 109:479–483PubMedCrossRef
20.
EURODIAB Substudy 2 Study Group (2002) Rapid early growth is associated with increased risk of childhood type 1 diabetes in various European populations. Diabetes Care 25:1755–1760CrossRef
21.
Hypponen E, Kenward MG, Virtanen SM et al (1999) Infant feeding, early weight gain, and risk of type 1 diabetes. Childhood Diabetes in Finland (DiMe) Study Group. Diabetes Care 22:1961–1965PubMedCrossRef
22.
Hypponen E, Virtanen SM, Kenward MG, Knip M, Akerblom HK (2000) Obesity, increased linear growth, and risk of type 1 diabetes in children. Diabetes Care 23:1755–1760PubMedCrossRef
23.
Johansson C, Samuelsson U, Ludvigsson J (1994) A high weight gain early in life is associated with an increased risk of type 1 (insulin-dependent) diabetes mellitus. Diabetologia 37:91–94PubMedCrossRef
24.
Larsson HE, Hansson G, Carlsson A et al (2008) Children developing type 1 diabetes before 6 years of age have increased linear growth independent of HLA genotypes. Diabetologia 51:1623–1630PubMedCrossRef
25.
Ljungkrantz M, Ludvigsson J, Samuelsson U (2008) Type 1 diabetes: increased height and weight gains in early childhood. Pediatr Diabetes 9:50–56PubMedCrossRef
26.
Pundziute-Lycka A, Persson LA, Cedermark G et al (2004) Diet, growth, and the risk for type 1 diabetes in childhood: a matched case-referent study. Diabetes Care 27:2784–2789PubMedCrossRef
27.
Viner RM, Hindmarsh PC, Taylor B, Cole TJ (2008) Childhood body mass index (BMI), breastfeeding and risk of Type 1 diabetes: findings from a longitudinal national birth cohort. Diabet Med 25:1056–1061PubMedCrossRef
28.
Couper JJ, Beresford S, Hirte C et al (2009) Weight gain in early life predicts risk of islet autoimmunity in children with a first-degree relative with type 1 diabetes. Diabetes Care 32:94–99PubMedCrossRef
29.
Rewers M, Bugawan TL, Norris JM et al (1996) Newborn screening for HLA markers associated with IDDM: diabetes autoimmunity study in the young (DAISY). Diabetologia. 39:807–812PubMedCrossRef
30.
Yu L, Rewers M, Gianani R et al (1996) Antiislet autoantibodies usually develop sequentially rather than simultaneously. J Clin Endocrinol Metab 81:4264–4267PubMedCrossRef
31.
Törn C, Mueller PW, Schlosser M, Bonifacio E, Bingley PJ, Participating Laboratories (2008) Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 51:846–852PubMedCrossRef
32.
Yu L, Robles DT, Abiru N et al (2000) Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. Proc Natl Acad Sci U S A 97:1701–1706PubMedCrossRef
33.
Stene LC, Barriga K, Hoffman M et al (2006) Normal but increasing hemoglobin A1c levels predict progression from islet autoimmunity to overt type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). Pediatr Diabetes 7:247–253PubMedCrossRef
34.
Moran A, Jacobs DR Jr, Steinberger J et al (1999) Insulin resistance during puberty: results from clamp studies in 357 children. Diabetes 48:2039–2044PubMedCrossRef
35.
Taylor SJ, Whincup PH, Hindmarsh PC, Lampe F, Odoki K, Cook DG (2001) Performance of a new pubertal self-assessment questionnaire: a preliminary study. Paediatr Perinat Epidemiol 15:88–94PubMedCrossRef
36.
Fitzmaurice GM, Laird NM, Ware JH (2004) Applied longitudinal analysis. Wiley, New Jersey, p 221
37.
Sontag MK, Corey M, Hokanson JE et al (2006) Genetic and physiologic correlates of longitudinal immunoreactive trypsinogen decline in infants with cystic fibrosis identified through newborn screening. J Pediatr 149:650–657PubMedCrossRef
38.
Rolland-Cachera MF, Deheeger M, Maillot M, Bellisle F (2006) Early adiposity rebound: causes and consequences for obesity in children and adults. Int J Obes Relat Metab Disord 30:S11–S17CrossRef
39.
Hindmarsh PC, Matthews DR, Di Silvio L, Kurtz AB, Brook CG (1988) Relation between height velocity and fasting insulin concentrations. Arch Dis Child 63:665–666PubMedCrossRef
40.
Ong KK, Petry CJ, Emmett PM et al (2004) Insulin sensitivity and secretion in normal children related to size at birth, postnatal growth, and plasma insulin-like growth factor-I levels. Diabetologia 47:1064–1070PubMed
41.
Xu P, Cuthbertson D, Greenbaum C, Palmer JP, Krischer JP, Diabetes Prevention Trial-Type 1 Study Group (2007) Role of insulin resistance in predicting progression to type 1 diabetes. Diabetes Care 30:2314–2320PubMedCrossRef
42.
Bingley PJ, Mahon JL, Gale EA, European Nicotinamide Diabetes Intervention Trial Group (2008) Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT). Diabetes Care 31:146–150PubMedCrossRef
43.
44.
Anjos S, Polychronakos C (2004) Mechanisms of genetic susceptibility to type I diabetes: beyond HLA. Mol Genet Metab 81:187–195PubMedCrossRef
45.
Heude B, Petry CJ, Avon Longitudinal Study of Parents Children (ALSPAC) study team, Pembrey M, Dunger DB, Ong KK (2006) The insulin gene variable number of tandem repeat: associations and interactions with childhood body fat mass and insulin secretion in normal children. J Clin Endocrinol Metab 91:2770–2775PubMedCrossRef
46.
Bjork E, Kampe O, Karlsson FA et al (1992) Glucose regulation of the autoantigen GAD65 in human pancreatic islets. J Clin Endocrinol Metab 75:1574–1576PubMedCrossRef
47.
Palmer JP, Helqvist S, Spinas GA et al (1989) Interaction of beta-cell activity and IL-1 concentration and exposure time in isolated rat islets of Langerhans. Diabetes 38:1211–1216PubMedCrossRef
48.
Mandrup-Poulsen T (1996) The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 39:1005–1029PubMedCrossRef
Metadata
Title
Height growth velocity, islet autoimmunity and type 1 diabetes development: the Diabetes Autoimmunity Study in the Young
Authors
M. M. Lamb
X. Yin
G. O. Zerbe
G. J. Klingensmith
D. Dabelea
T. E. Fingerlin
M. Rewers
J. M. Norris
Publication date
01-10-2009
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 10/2009
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1428-2

Other articles of this Issue 10/2009

Diabetologia 10/2009 Go to the issue

Article

C-peptide is internalised in human endothelial and vascular smooth muscle cells via early endosomes

Article

Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial

Letter

Diabetic retinopathy and insulin glargine

Article

Regulation of skeletal muscle sucrose, non-fermenting 1/AMP-activated protein kinase-related kinase (SNARK) by metabolic stress and diabetes

Article

Regulation of insulin gene expression by cytokines and cell–cell interactions in mouse medullary thymic epithelial cells

Review

Novel pharmacological approaches to combat obesity and insulin resistance: targeting skeletal muscle with ‘exercise mimetics’
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits